Edurne Arriola

3.8k total citations
122 papers, 2.3k citations indexed

About

Edurne Arriola is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Edurne Arriola has authored 122 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Oncology, 64 papers in Pulmonary and Respiratory Medicine and 26 papers in Molecular Biology. Recurrent topics in Edurne Arriola's work include Lung Cancer Treatments and Mutations (58 papers), Lung Cancer Research Studies (44 papers) and Cancer Immunotherapy and Biomarkers (25 papers). Edurne Arriola is often cited by papers focused on Lung Cancer Treatments and Mutations (58 papers), Lung Cancer Research Studies (44 papers) and Cancer Immunotherapy and Biomarkers (25 papers). Edurne Arriola collaborates with scholars based in Spain, United States and United Kingdom. Edurne Arriola's co-authors include Joan Albanell, Álvaro Taus, Christian H. Ottensmeier, Ana Rovira, Lara Pijuán, Marta Salido, Israel Cañadas, Enrique Grande, Jorge S. Reis‐Filho and Mitch Dowsett and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Edurne Arriola

117 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Edurne Arriola Spain	27	1.4k	931	662	604	268	122	2.3k
Guanghui Gao China	30	1.5k 1.1×	1.4k 1.5×	811 1.2×	620 1.0×	155 0.6×	86	2.5k
Michael Allgäuer Germany	23	790 0.6×	794 0.9×	438 0.7×	489 0.8×	122 0.5×	67	1.9k
Akhil Chawla United States	13	1.9k 1.3×	570 0.6×	614 0.9×	638 1.1×	202 0.8×	44	2.5k
Shigetsugu Takano Japan	28	1.2k 0.9×	417 0.4×	1.0k 1.5×	466 0.8×	277 1.0×	124	2.3k
Taishi Harada Japan	27	1.5k 1.1×	1.4k 1.5×	855 1.3×	316 0.5×	194 0.7×	114	2.6k
Mishie Tanino Japan	25	533 0.4×	650 0.7×	961 1.5×	497 0.8×	263 1.0×	117	2.3k
Teruhiko Yoshida Japan	24	1.1k 0.8×	974 1.0×	1.1k 1.6×	464 0.8×	103 0.4×	54	2.2k
Antonella Argentiero Italy	23	794 0.6×	326 0.4×	596 0.9×	427 0.7×	162 0.6×	48	1.6k
Jianhua Zhan China	21	1.6k 1.1×	1.0k 1.1×	465 0.7×	461 0.8×	100 0.4×	52	2.2k
Fengshen Kuo United States	19	1.3k 1.0×	770 0.8×	819 1.2×	519 0.9×	135 0.5×	56	2.4k

Countries citing papers authored by Edurne Arriola

Since Specialization

Citations

This map shows the geographic impact of Edurne Arriola's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edurne Arriola with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edurne Arriola more than expected).

Fields of papers citing papers by Edurne Arriola

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edurne Arriola. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edurne Arriola. The network helps show where Edurne Arriola may publish in the future.

Co-authorship network of co-authors of Edurne Arriola

This figure shows the co-authorship network connecting the top 25 collaborators of Edurne Arriola. A scholar is included among the top collaborators of Edurne Arriola based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edurne Arriola. Edurne Arriola is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rocha, Pedro, Sílvia Menéndez, Ignacio Sánchez, et al.. (2025). The Potential of Single-Transcription Factor Gene Expression by RT-qPCR for Subtyping Small Cell Lung Cancer. International Journal of Molecular Sciences. 26(3). 1293–1293. 2 indexed citations

Arriola, Edurne, Jacqulyne Robichaux, Vang Quy Le, et al.. (2025). 1817MO Molecular residual disease (MRD) analysis from the LAURA study of osimertinib (osi) in unresectable (UR) stage III EGFR-mutated (EGFRm) NSCLC. Annals of Oncology. 36. S982–S982.

Wermke, Martin, Valentina Gambardella, Yasutoshi Kuboki, et al.. (2025). Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas. Journal of Clinical Oncology. 43(27). 3021–3031. 4 indexed citations

Isla, Dolores, Rosa Álvarez, María José Domper-Arnal, et al.. (2024). Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis. Journal of Medical Economics. 27(1). 1379–1387. 3 indexed citations

Wermke, Martin, Valentina Gambardella, Yasutoshi Kuboki, et al.. (2024). OA10.05 Phase I Trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3-Positive Tumors: Patients with LCNEC. Journal of Thoracic Oncology. 19(10). S32–S32. 1 indexed citations

Park, K., Edurne Arriola, M. Pérol, et al.. (2024). P1.12B.10 Dose Adjustments and Exposure-Response Associated with Selpercatinib in Patients with Advanced NSCLC. Journal of Thoracic Oncology. 19(10). S205–S205. 1 indexed citations

Garcia, Juan, et al.. (2023). Equitable access to oncology clinical trials: harnessing technology to reduce geographic disparities. SHILAP Revista de lepidopterología. 2. 100006–100006. 2 indexed citations

Kuboki, Yasutoshi, Valentina Gambardella, Olatunji B. Alese, et al.. (2023). 75MO Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3+ tumors: Focus on Asian pts. Annals of Oncology. 34. S1495–S1495.

Wermke, Martin, Yasutoshi Kuboki, Enriqueta Felip, et al.. (2023). OA01.05 Phase I Dose Escalation Trial Of The DLL3/CD3 Igg-Like T Cell Engager BI 764532 In Patients with DLL3+ Tumors: Focus on SCLC. Journal of Thoracic Oncology. 18(11). S45–S46. 3 indexed citations

10.

Goto, Keiko, Benjamin Solomon, K. Park, et al.. (2023). LBA4 Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC. Annals of Oncology. 34. S1303–S1303. 4 indexed citations

11.

Arriola, Edurne, M.R. García-Campelo, Margarita Majem, et al.. (2023). 1993P Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results. Annals of Oncology. 34. S1063–S1063. 3 indexed citations

12.

Arriola, Edurne, Reyes Bernabé, Rosario García Campelo, et al.. (2023). Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non–Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers. JCO Precision Oncology. 7(7). e2200546–e2200546. 26 indexed citations

13.

Solomon, Benjamin, Alexander Drilon, Keunchil Park, et al.. (2020). Phase III Study of Selpercatinib Versus Chemotherapy ± pembrolizumab in Untreated RET Positive Non-Small-Cell Lung Cancer. Future Oncology. 17(7). 763–773. 30 indexed citations

14.

Clavé, Sergi, Lara Pijuán, Marta Lorenzo, et al.. (2019). Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non–small-cell Lung Cancer: Implications of FISH-positive Patterns. Clinical Lung Cancer. 20(4). e421–e429. 33 indexed citations

15.

Arriola, Edurne, et al.. (2019). MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside. Cancers. 11(10). 1404–1404. 10 indexed citations

16.

Arriola, Edurne, Ramón García Gómez, Pilar Díz, et al.. (2018). Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. BMC Cancer. 18(1). 106–106. 14 indexed citations

17.

Rocha, Pedro, Álvaro Taus, Maria Teresa Rodrigo‐Calvo, et al.. (2018). CD103+CD8+ Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC. Journal of Thoracic Oncology. 13(10). e193–e196. 24 indexed citations

18.

Cañadas, Israel, Federico Rojo, Álvaro Taus, et al.. (2013). Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer. Clinical Cancer Research. 20(4). 938–950. 107 indexed citations

19.

Arriola, Edurne, Socorro Marıá Rodríguez-Pinilla, Maryou B. Lambros, et al.. (2007). Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Research and Treatment. 106(2). 181–189. 87 indexed citations

20.

Jones, Robin L., Maryou B. Lambros, Edurne Arriola, et al.. (2007). MYC amplification in breast cancer: A chromogenic in situ hybridisation study. Laboratory Investigation. 87(9). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact